This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
A single intramuscular dose of an experimental malaria monoclonal antibody safely provided infants with strong protection during Mali's six-month malaria season. However, potential interference with the R21 malaria vaccine is putting plans to pursue development of L9LS for this age group on hold, according to results from a clinical trial presented at the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).
The Phase Ib trial involved a monoclonal antibody known as L9LS that was developed by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The antibody has a strong track record of safety and efficacy in clinical trials involving older children in Mali and Kenya.
"We wanted to test L9LS in infants as young as 1 month old, because children are not eligible for malaria vaccination until they are at least 5 months old—and that leaves them especially vulnerable, particularly during times of intense malaria transmission," said Kassoum Kayentao, a physician-scientist at the University of Sciences, Techniques and Technologies in Bamako, Mali, which conducted the trial in partnership with NIAID colleagues.
"While protective efficacy against malaria infection was 78%, the monoclonal antibody also appeared to interfere with the immune response to subsequent immunization with the R21 malaria vaccine, which is widely used in Mali.
Source link







